drugset / Trial / NCT00639327

Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

NCT00639327

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is compare overall survival of the test arm (CPT-11/S-1 combination) to the control arm (CPT-11 alone) in the subjects with S-1 refractory advanced gastric cancer.

Timeline

Start
2008-03
Primary completion
2011-04
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Irinotecan Small molecule 150 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg/m2 Oral
Subject S-1 Small molecule 60 mg/m2 Oral

Indications